R-Pharm has filed an innovative COVID-19 medicine patent application

March 30

March 30, 2019 – R-Pharm Group has filed its first international patent application regarding biotech medicine that binds viral particles of COVID-19 and prevents them from penetrating alveolar cells.

“Research and development of this medicine is on early stages. Despite that, it is very important for us, so we decided to speed it up. We believe, that along with other promising drug candidates, this molecule is on its way to land a decisive strike against COVID-19 both in Russia and around the world”, stated R-Pharm’s chairman of the board Alexey Repik.

Group has launched a set of comprehensive measures aiming to curb COVID-19 pandemic. These measures range from development of new molecules and therapy methods to reevaluation of the current product portfolio.

Other company news

R-Pharm Group of Companies successfully registered Artlegia (olokizumab), a novel drug for treatment of rheumatoid arthritis in the first...
read more...
May 29
R-Pharm JSC has obtained official permission to conduct clinical trial in Russia to evaluate the efficacy and safety of radotinib for...
read more...
May 28
Deltyba® (delamanid) —an essential medicine according to the World Health Organization [1]—is now available in Russia for...
read more...
May 25